Department of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Division of Cardiac Surgery, Brigham and Women's Hospital, Harvard Medical School, Massachusetts, Boston, USA.
J Card Surg. 2021 Jul;36(7):2442-2451. doi: 10.1111/jocs.15570. Epub 2021 Apr 24.
The opioid epidemic has seen a drastic increase in the incidence of drug-associated infective endocarditis (IE). No clinical tool exists to predict operative morbidity and mortality in patients undergoing surgery.
A multi-institutional database was reviewed between 2011 and 2018. Multivariate logistic regression was fitted in an automated stepwise fashion. The STratification risk analysis in OPerative management of drug-associated IE (STOP) score was constructed. Morbidity was defined as reintubation, prolonged ventilation, pneumonia, renal failure, dialysis, stroke, reoperation for bleeding, and a permanent pacemaker. Cross-validation provided an unbiased estimate of out-of-sample performance.
A total of 1181 patients underwent surgery for drug-associated IE (median age, 39; interquartile range [IQR], 30-54, 386 women [32.7%], 341 reoperations for prosthetic valve endocarditis [28.9%], 316 patients with multivalve disease [26.8%]). Operative morbidity and mortality were 41.1% and 5.9%, respectively. Predictors of morbidity were dialysis (95% confidence interval [CI], 1.16-2.82), emergent intervention (1.83-4.73), multivalve procedure (1.01-1.98), causative organisms other than Streptococcus (1.09-2.02), and type of valve procedure performed [aortic valve procedure (1.07-2.15), mitral valve replacement (1.03-2.05), tricuspid valve replacement (1.21-2.60)]. Predictors of mortality were dialysis (1.29-5.74), active endocarditis (1.32-83), lung disease (1.25-5.43), emergent intervention (1.69-6.60), prosthetic valve endocarditis (1.24-3.69), aortic valve procedure (1.49-5.92) and multivalve disease (1.00-2.95). Variables maximizing explanatory power were translated into a scoring system. Each point increased odds of morbidity and mortality by 22.0% and 22.4% with an accuracy of 94.0% and 94.1%, respectively.
Drug-related IE is associated with significant morbidity and mortality. An easily-applied risk stratification score may aid in clinical decision-making.
阿片类药物泛滥导致药物相关性感染性心内膜炎(IE)发病率急剧上升。目前尚无临床工具可预测接受手术治疗的患者的手术发病率和死亡率。
回顾了 2011 年至 2018 年的多机构数据库。采用自动化逐步法进行多变量逻辑回归分析。构建了用于药物相关性 IE(STOP)手术管理的风险分析 Stratification risk analysis in OPerative management of drug-associated IE(STOP)评分。发病率定义为再插管、长时间通气、肺炎、肾衰竭、透析、中风、因出血而再次手术以及永久性起搏器。交叉验证提供了样本外性能的无偏估计。
共有 1181 例患者因药物相关性 IE 接受手术治疗(中位年龄 39 岁;四分位距 [IQR],30-54,386 名女性[32.7%],341 例再次行人工瓣膜心内膜炎手术[28.9%],316 例多瓣膜疾病[26.8%])。手术发病率和死亡率分别为 41.1%和 5.9%。发病率的预测因素为透析(95%置信区间 [CI],1.16-2.82)、紧急干预(1.83-4.73)、多瓣膜手术(1.01-1.98)、致病微生物不是链球菌(1.09-2.02)以及手术瓣膜类型[主动脉瓣手术(1.07-2.15),二尖瓣置换术(1.03-2.05),三尖瓣置换术(1.21-2.60)]。死亡率的预测因素为透析(1.29-5.74)、活动性心内膜炎(1.32-83)、肺部疾病(1.25-5.43)、紧急干预(1.69-6.60)、人工瓣膜心内膜炎(1.24-3.69)、主动脉瓣手术(1.49-5.92)和多瓣膜疾病(1.00-2.95)。最大化解释能力的变量被转化为评分系统。每个积分点会使发病率和死亡率分别增加 22.0%和 22.4%,准确性分别为 94.0%和 94.1%。
药物相关性 IE 与较高的发病率和死亡率相关。一种易于应用的风险分层评分系统可能有助于临床决策。